This study, generated in the framework of an institutional Italian multicenter working group on CLL (“Campus CLL”), is a retrospective/multicenter analysis of 229 CLL patients treated with ibrutinib in the current clinical practice. All cases have been either referred to a single institution for molecular and cytogenetic analyses (February 2014–February 2021), or retrospectively referred by delivering frozen cell samples taken prior to starting ibrutinib treatment.
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study / Bomben, Riccardo; Rossi, Francesca Maria; Vit, Filippo; Bittolo, Tamara; Zucchetto, Antonella; Papotti, Robel; Tissino, Erika; Pozzo, Federico; Degan, Massimo; Polesel, Jerry; Bulian, Pietro; Marasca, Roberto; Reda, Gianluigi; Laurenti, Luca; Olivieri, Jacopo; Chiarenza, Annalisa; Laureana, Roberta; Postorino, Massimiliano; Del Principe, Maria Ilaria; Cuneo, Antonio; Gentile, Massimo; Morabito, Fortunato; Fronza, Gilberto; Tafuri, Agostino; Zaja, Francesco; Foà, Robin; Di Raimondo, Francesco; Del Poeta, Giovanni; Gattei, Valter. - In: LEUKEMIA. - ISSN 1476-5551. - 37:4(2023), pp. 914-918. [10.1038/s41375-023-01845-9]
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
Tafuri, Agostino;Foà, Robin;
2023
Abstract
This study, generated in the framework of an institutional Italian multicenter working group on CLL (“Campus CLL”), is a retrospective/multicenter analysis of 229 CLL patients treated with ibrutinib in the current clinical practice. All cases have been either referred to a single institution for molecular and cytogenetic analyses (February 2014–February 2021), or retrospectively referred by delivering frozen cell samples taken prior to starting ibrutinib treatment.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bomben_Clinical-impact_2023.pdf
accesso aperto
Note: letter
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
